XNCR
Xencor, Inc.
Price Chart
Latest Quote
$12.11
Current Price| Previous Close | $12.09 |
| Open | $12.00 |
| Day High | $12.42 |
| Day Low | $11.85 |
| Volume | 534,193 |
Stock Information
| Shares Outstanding | 71.41M |
| Total Debt | $202.40M |
| Cash Equivalents | $471.04M |
| Revenue | $150.13M |
| Net Income | $-130.82M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $864.78M |
| EPS (TTM) | $-1.73 |
| Exchange | NGM |
📊 Custom Metrics & Score
Score: 18/42| Debt to Equity | 0.34 |
| Debt to Earnings | -0.99 |
| Current Ratio | 6.61 |
| Quick Ratio | 6.39 |
| Avg Revenue Growth | -14.96% |
| Profit Margin | -210.53% |
| Return on Equity | -34.33% |
| Avg FCF Growth | 136.19% |
| FCF Yield | -24.48% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $12.11 | 556,499 |
| 2026-01-30 | $12.09 | 565,400 |
| 2026-01-29 | $12.38 | 406,300 |
| 2026-01-28 | $12.35 | 635,100 |
| 2026-01-27 | $13.17 | 352,600 |
| 2026-01-26 | $13.02 | 641,200 |
| 2026-01-23 | $12.78 | 616,800 |
| 2026-01-22 | $13.11 | 735,100 |
| 2026-01-21 | $13.00 | 679,000 |
| 2026-01-20 | $12.64 | 869,700 |
| 2026-01-16 | $12.79 | 673,500 |
| 2026-01-15 | $13.21 | 514,900 |
| 2026-01-14 | $14.45 | 560,200 |
| 2026-01-13 | $13.94 | 517,000 |
| 2026-01-12 | $14.17 | 930,900 |
| 2026-01-09 | $13.89 | 1,397,200 |
| 2026-01-08 | $14.19 | 931,700 |
| 2026-01-07 | $14.95 | 1,595,900 |
| 2026-01-06 | $14.06 | 1,109,900 |
| 2026-01-05 | $14.27 | 723,400 |
About Xencor, Inc.
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; and Sotrovimab that targets the SARS-CoV-2 virus. It develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; Vudalimab, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer; XmAb564, to treat autoimmune diseases; XmAb662, which is in Phase I clinical trial to treat patients with solid tumors; XmAb942, which is in Phase I clinical trial for patients with Crohn's disease and ulcerative colitis; and Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat lymphoma. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; Obexelimab, to treat patients with immunoglobulin G4-related disease; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Tobevibart, a treatment for hepatitis Delta virus infection; Novartis, an antibody drug candidate that uses XmAb Fc technologies; Xpro1595 to treat patients with Alzheimer's disease and treatment-resistant depression; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat prostate cancer; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.
📰 Latest News
Xencor (XNCR): BofA Bullish on US Biopharmaceuticals Coverage
Insider Monkey • 2026-01-30T05:24:19Z
Could Early XmAb819 Signals Reshape Xencor’s (XNCR) Broader T‑Cell Engager Investment Narrative?
Simply Wall St. • 2026-01-20T12:07:47Z
Xencor (XNCR) Valuation Check After New Oncology And Autoimmune Pipeline Milestones
Simply Wall St. • 2026-01-19T02:10:10Z
Calculating The Fair Value Of Xencor, Inc. (NASDAQ:XNCR)
Simply Wall St. • 2025-12-31T10:46:49Z
Xencor (XNCR): Assessing Valuation After Net Losses Narrow Sharply in Latest Earnings
Simply Wall St. • 2025-11-14T11:14:20Z
Will Sharply Reduced Net Losses Signal a Turning Point for Xencor's (XNCR) Path to Profitability?
Simply Wall St. • 2025-11-13T21:10:51Z
Xencor (XNCR) Reports Q3 Loss, Misses Revenue Estimates
Zacks • 2025-11-05T22:35:05Z
Xencor: Q3 Earnings Snapshot
Associated Press Finance • 2025-11-05T21:47:12ZBeaten Down by 35%-Plus: Analysts Say These 2 Oversold Stocks Are Poised to Turn the Corner
TipRanks • 2025-11-05T11:08:08Z
Aurinia Pharmaceuticals (AUPH) Surpasses Q3 Earnings and Revenue Estimates
Zacks • 2025-11-04T12:10:02Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Revenue | $110,493,000 | $174,615,000 | $164,579,000 | $275,111,000 |
| Operating Revenue | $110,493,000 | $174,615,000 | $164,579,000 | $275,111,000 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $36,643,000 | $6,177,000 | $13,000 | $13,000 |
| Total Expenses | $288,901,000 | $306,977,000 | $247,052,000 | $231,344,000 |
| Other Income Expense | $-51,802,000 | $-426,000 | $23,148,000 | $38,015,000 |
| Other Non Operating Income Expenses | $50,000 | $-31,000 | $-148,000 | $-1,274,000 |
| Net Non Operating Interest Income Expense | $-4,713,000 | $13,154,000 | $4,817,000 | $849,000 |
| Interest Expense Non Operating | $36,643,000 | $6,177,000 | $13,000 | $13,000 |
| Operating Expense | $288,901,000 | $306,977,000 | $247,052,000 | $231,344,000 |
| General And Administrative Expense | $61,215,000 | $53,379,000 | $47,489,000 | $38,837,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-232,618,000 | $-133,133,000 | $-55,181,000 | $82,631,000 |
| Net Interest Income | $-4,713,000 | $13,154,000 | $4,817,000 | $849,000 |
| Interest Income | $31,930,000 | $19,331,000 | $4,830,000 | $862,000 |
| Normalized Income | $-191,654,920 | $-132,820,950 | $-73,584,840 | $43,342,000 |
| Net Income From Continuing And Discontinued Operation | $-232,618,000 | $-133,133,000 | $-55,181,000 | $82,631,000 |
| Total Operating Income As Reported | $-178,408,000 | $-132,362,000 | $-82,473,000 | $43,767,000 |
| Net Income Common Stockholders | $-232,618,000 | $-133,133,000 | $-55,181,000 | $82,631,000 |
| Net Income | $-232,618,000 | $-133,133,000 | $-55,181,000 | $82,631,000 |
| Net Income Including Noncontrolling Interests | $-236,540,000 | $-133,296,000 | $-55,181,000 | $82,631,000 |
| Net Income Continuous Operations | $-236,540,000 | $-133,296,000 | $-55,181,000 | $82,631,000 |
| Pretax Income | $-234,923,000 | $-119,634,000 | $-54,508,000 | $82,631,000 |
| Special Income Charges | $-20,430,000 | $0 | $-138,000 | - |
| Interest Income Non Operating | $31,930,000 | $19,331,000 | $4,830,000 | $862,000 |
| Operating Income | $-178,408,000 | $-132,362,000 | $-82,473,000 | $43,767,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-3.58 | $-2.08 | $-0.93 | $1.37 |
| Basic EPS | $-3.58 | $-2.08 | $-0.93 | $1.42 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $-10,888,920 | $-82,950 | $4,892,160 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-134,321,000 | $-101,564,000 | $-68,992,000 | $50,846,000 |
| Total Unusual Items | $-51,852,000 | $-395,000 | $23,296,000 | $39,289,000 |
| Total Unusual Items Excluding Goodwill | $-51,852,000 | $-395,000 | $23,296,000 | $39,289,000 |
| Reconciled Depreciation | $12,107,000 | $11,498,000 | $8,799,000 | $7,491,000 |
| EBITDA (Bullshit earnings) | $-186,173,000 | $-101,959,000 | $-45,696,000 | $90,135,000 |
| EBIT | $-198,280,000 | $-113,457,000 | $-54,495,000 | $82,644,000 |
| Diluted Average Shares | $65,041,265 | $60,503,283 | $59,652,461 | $60,495,455 |
| Basic Average Shares | $65,041,265 | $60,503,283 | $59,652,461 | $58,379,641 |
| Diluted NI Availto Com Stockholders | $-232,618,000 | $-133,133,000 | $-55,181,000 | $82,631,000 |
| Minority Interests | $3,922,000 | $163,000 | $0 | $0 |
| Tax Provision | $1,617,000 | $13,662,000 | $673,000 | $0 |
| Write Off | $20,430,000 | $0 | $138,000 | - |
| Gain On Sale Of Security | $-31,422,000 | $-395,000 | $23,434,000 | $39,289,000 |
| Research And Development | $227,686,000 | $253,598,000 | $199,563,000 | $192,507,000 |
| Selling General And Administration | $61,215,000 | $53,379,000 | $47,489,000 | $38,837,000 |
| Other Gand A | $61,215,000 | $53,379,000 | $47,489,000 | $38,837,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $659,126,000 | $643,087,000 | $708,996,000 | $717,011,000 |
| Total Assets | $951,945,000 | $965,135,000 | $846,266,000 | $838,211,000 |
| Total Non Current Assets | $374,344,000 | $329,532,000 | $170,924,000 | $413,843,000 |
| Other Non Current Assets | $885,000 | $1,028,000 | $613,000 | $653,000 |
| Investmentin Financial Assets | $256,833,000 | $209,722,000 | $58,209,000 | $331,727,000 |
| Goodwill And Other Intangible Assets | $18,485,000 | $18,663,000 | $18,500,000 | $16,493,000 |
| Other Intangible Assets | $18,485,000 | $18,663,000 | $18,500,000 | $16,493,000 |
| Current Assets | $577,601,000 | $635,603,000 | $675,342,000 | $424,368,000 |
| Other Current Assets | $18,977,000 | $18,139,000 | $23,283,000 | $23,877,000 |
| Receivables | $60,849,000 | $23,739,000 | $28,997,000 | $66,384,000 |
| Accounts Receivable | $60,849,000 | $23,739,000 | $28,997,000 | $66,384,000 |
| Cash Cash Equivalents And Short Term Investments | $497,775,000 | $593,725,000 | $623,062,000 | $334,107,000 |
| Cash And Cash Equivalents | $40,875,000 | $53,790,000 | $53,942,000 | $143,480,000 |
| Non Current Note Receivables | - | - | $0 | $5,000,000 |
| Prepaid Assets | - | - | - | $23,877,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Debt | $122,731,000 | $135,693,000 | - | - |
| Total Debt | $231,953,000 | $251,943,000 | $59,634,000 | $33,969,000 |
| Long Term Debt And Capital Lease Obligation | $180,497,000 | $220,797,000 | $54,926,000 | $33,969,000 |
| Long Term Debt | $115,159,000 | $161,772,000 | - | - |
| Current Debt And Capital Lease Obligation | $51,456,000 | $31,146,000 | $4,708,000 | - |
| Current Debt | $48,447,000 | $27,711,000 | - | - |
| Other Current Borrowings | $48,447,000 | $27,711,000 | - | - |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $277,919,000 | $303,048,000 | $118,770,000 | $104,707,000 |
| Total Non Current Liabilities Net Minority Interest | $190,487,000 | $229,133,000 | $54,926,000 | $33,969,000 |
| Tradeand Other Payables Non Current | $9,990,000 | $8,336,000 | $0 | - |
| Current Liabilities | $87,432,000 | $73,915,000 | $63,844,000 | $70,738,000 |
| Payables And Accrued Expenses | $35,976,000 | $42,769,000 | $28,816,000 | $33,444,000 |
| Payables | $16,759,000 | $19,205,000 | $10,088,000 | $14,001,000 |
| Total Tax Payable | $0 | $5,291,000 | $0 | - |
| Income Tax Payable | $0 | $5,291,000 | $0 | - |
| Accounts Payable | $16,759,000 | $13,914,000 | $10,088,000 | $14,001,000 |
| Non Current Deferred Liabilities | - | $125,183,000 | $0 | - |
| Current Deferred Liabilities | - | $0 | $30,320,000 | $37,294,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $677,611,000 | $661,750,000 | $727,496,000 | $733,504,000 |
| Total Equity Gross Minority Interest | $674,026,000 | $662,087,000 | $727,496,000 | $733,504,000 |
| Stockholders Equity | $677,611,000 | $661,750,000 | $727,496,000 | $733,504,000 |
| Gains Losses Not Affecting Retained Earnings | $-663,000 | $1,291,000 | $-6,952,000 | $-1,510,000 |
| Other Equity Adjustments | $-663,000 | $1,291,000 | $-6,952,000 | $-1,510,000 |
| Retained Earnings | $-704,036,000 | $-471,418,000 | $-338,285,000 | $-283,104,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $70,256,108 | $60,998,191 | $59,997,713 | $59,355,558 |
| Share Issued | $70,256,108 | $60,998,191 | $59,997,713 | $59,355,558 |
| Tangible Book Value | $659,126,000 | $643,087,000 | $708,996,000 | $717,011,000 |
| Invested Capital | $841,217,000 | $851,233,000 | $727,496,000 | $733,504,000 |
| Working Capital | $490,169,000 | $561,688,000 | $611,498,000 | $353,630,000 |
| Capital Lease Obligations | $68,347,000 | $62,460,000 | $59,634,000 | $33,969,000 |
| Total Capitalization | $792,770,000 | $823,522,000 | $727,496,000 | $733,504,000 |
| Minority Interest | $-3,585,000 | $337,000 | $0 | - |
| Additional Paid In Capital | $1,381,607,000 | $1,131,266,000 | $1,072,132,000 | $1,017,523,000 |
| Capital Stock | $703,000 | $611,000 | $601,000 | $595,000 |
| Common Stock | $703,000 | $611,000 | $601,000 | $595,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $65,338,000 | $59,025,000 | $54,926,000 | $33,969,000 |
| Current Capital Lease Obligation | $3,009,000 | $3,435,000 | $4,708,000 | $0 |
| Current Accrued Expenses | $19,217,000 | $23,564,000 | $18,728,000 | $19,443,000 |
| Investments And Advances | $256,833,000 | $209,722,000 | $58,209,000 | $331,727,000 |
| Available For Sale Securities | $256,833,000 | $209,722,000 | $58,209,000 | $331,727,000 |
| Net PPE | $98,141,000 | $100,119,000 | $93,602,000 | $59,970,000 |
| Accumulated Depreciation | $-42,179,000 | $-36,226,000 | $-28,289,000 | $-22,828,000 |
| Gross PPE | $140,320,000 | $136,345,000 | $121,891,000 | $82,798,000 |
| Leases | $54,788,000 | $52,410,000 | $41,774,000 | $8,574,000 |
| Other Properties | $38,341,000 | $33,995,000 | $34,419,000 | $31,730,000 |
| Machinery Furniture Equipment | $47,191,000 | $49,940,000 | $45,698,000 | $42,494,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $456,900,000 | $539,935,000 | $569,120,000 | $190,627,000 |
| Treasury Shares Number | - | $0 | - | - |
| Non Current Deferred Revenue | - | $125,183,000 | $0 | - |
| Current Deferred Revenue | - | $0 | $30,320,000 | $37,294,000 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-211,700,000 | $-99,177,000 | $-18,919,000 | $-32,834,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-202,188,000 | $-77,926,000 | $24,485,000 | $-16,853,000 |
| Cash Flow From Continuing Operating Activities | $-202,188,000 | $-77,926,000 | $24,485,000 | $-16,853,000 |
| Operating Gains Losses | $3,869,000 | $2,646,000 | $1,655,000 | $-1,904,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-9,512,000 | $-21,251,000 | $-43,404,000 | $-15,981,000 |
| Investing Cash Flow | $-7,872,000 | $-111,065,000 | $-119,725,000 | $-46,249,000 |
| Cash Flow From Continuing Investing Activities | $-7,872,000 | $-111,065,000 | $-119,725,000 | $-46,249,000 |
| Net Other Investing Changes | - | - | $5,000,000 | $-5,842,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Issuance Of Capital Stock | $201,256,000 | $0 | $0 | $28,920,000 |
| Financing Cash Flow | $197,152,000 | $189,219,000 | $5,702,000 | $43,038,000 |
| Cash Flow From Continuing Financing Activities | $197,152,000 | $189,219,000 | $5,702,000 | $43,038,000 |
| Net Other Financing Charges | $-12,077,000 | $183,830,000 | - | - |
| Net Common Stock Issuance | $201,256,000 | $0 | $0 | $28,920,000 |
| Common Stock Issuance | $201,256,000 | $0 | $0 | $28,920,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Paid Supplemental Data | $33,000 | $22,000 | $13,000 | $14,000 |
| Income Tax Paid Supplemental Data | $6,100,000 | $0 | $700,000 | $0 |
| End Cash Position | $41,262,000 | $54,170,000 | $53,942,000 | $143,480,000 |
| Beginning Cash Position | $54,170,000 | $53,942,000 | $143,480,000 | $163,544,000 |
| Changes In Cash | $-12,908,000 | $228,000 | $-89,538,000 | $-20,064,000 |
| Proceeds From Stock Option Exercised | $7,973,000 | $5,389,000 | $5,702,000 | $14,118,000 |
| Net Investment Purchase And Sale | $1,640,000 | $-89,815,000 | $-81,321,000 | $-24,445,000 |
| Sale Of Investment | $596,694,000 | $693,090,000 | $306,607,000 | $485,152,000 |
| Purchase Of Investment | $-595,054,000 | $-782,905,000 | $-387,928,000 | $-509,597,000 |
| Net Intangibles Purchase And Sale | $-3,415,000 | $-2,803,000 | $-4,910,000 | $-2,682,000 |
| Purchase Of Intangibles | $-3,415,000 | $-2,803,000 | $-4,910,000 | $-2,682,000 |
| Net PPE Purchase And Sale | $-6,097,000 | $-18,447,000 | $-38,494,000 | $-13,280,000 |
| Sale Of PPE | $0 | $1,000 | $0 | $19,000 |
| Purchase Of PPE | $-6,097,000 | $-18,448,000 | $-38,494,000 | $-13,299,000 |
| Change In Working Capital | $-40,400,000 | $19,133,000 | $48,865,000 | $-102,601,000 |
| Change In Other Working Capital | $-2,943,000 | $-13,437,000 | $16,002,000 | $-54,110,000 |
| Change In Payables And Accrued Expense | $-1,502,000 | $8,662,000 | $-4,628,000 | $6,887,000 |
| Change In Accrued Expense | $-4,347,000 | $4,836,000 | $-715,000 | $1,840,000 |
| Change In Payable | $2,845,000 | $3,826,000 | $-3,913,000 | $5,047,000 |
| Change In Account Payable | $2,845,000 | $3,826,000 | $-3,913,000 | $5,047,000 |
| Change In Prepaid Assets | $159,000 | $5,103,000 | $634,000 | $-13,592,000 |
| Change In Receivables | $-36,114,000 | $18,805,000 | $36,857,000 | $-41,786,000 |
| Changes In Account Receivables | $-32,673,000 | $19,833,000 | $37,387,000 | $-42,441,000 |
| Other Non Cash Items | $-30,313,000 | $-18,422,000 | $-5,397,000 | $-22,379,000 |
| Stock Based Compensation | $53,281,000 | $53,755,000 | $48,913,000 | $36,975,000 |
| Unrealized Gain Loss On Investment Securities | $31,422,000 | $395,000 | $-23,434,000 | $-20,988,000 |
| Asset Impairment Charge | $20,430,000 | $0 | $138,000 | $762,000 |
| Amortization Of Securities | $-16,044,000 | $-13,635,000 | $127,000 | $3,160,000 |
| Depreciation Amortization Depletion | $12,107,000 | $11,498,000 | $8,799,000 | $7,491,000 |
| Depreciation And Amortization | $12,107,000 | $11,498,000 | $8,799,000 | $7,491,000 |
| Gain Loss On Investment Securities | $-37,000 | - | - | $-3,300,000 |
| Gain Loss On Sale Of PPE | $2,329,000 | $1,267,000 | $1,510,000 | $934,000 |
| Net Income From Continuing Operations | $-236,540,000 | $-133,296,000 | $-55,181,000 | $82,631,000 |
| Change In Tax Payable | - | $13,633,000 | $0 | $0 |
| Change In Income Tax Payable | - | $13,633,000 | $0 | $0 |